Sign In
Buy BCDA
$0.87
-0.0256 (-2.84%)
At Close: Jun 03, 2026
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results
04:05pm, Wednesday, 14'th May 2025
SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
04:28pm, Friday, 09'th May 2025
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
Insider Buying Surges in May. Especially These 5 Stocks
10:23am, Wednesday, 07'th May 2025
The Securities Act of 1934 established many of the US rules for the securities market in the aftermath of the 1929 Stock Market Crash that ushered in The Great Depression.
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
09:15am, Friday, 11'th Apr 2025
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress
BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript
11:30pm, Monday, 31'st Mar 2025
BioCardia, Inc. (NASDAQ:BCDA ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief
BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
01:39pm, Monday, 31'st Mar 2025
SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dise
BioCardia Reports 2024 Business Highlights and Financial Results
04:30pm, Wednesday, 26'th Mar 2025
SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
08:30am, Friday, 21'st Mar 2025
SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
09:15am, Monday, 10'th Mar 2025
SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dis
SUNNYVALE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
Focus on Patients with Elevated Markers of Heart Stress and Inflammation Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery SUNNYVALE, Calif., Feb. 13, 2025 (
SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have b
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure
08:30am, Wednesday, 04'th Dec 2024
SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript
07:49pm, Wednesday, 13'th Nov 2024
BioCardia, Inc. (NASDAQ:BCDA ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chi
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
08:30am, Wednesday, 18'th Sep 2024
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
